With over 0.19 million Cocrystal Pharma Inc. (COCP) shares trading Tuesday and a closing price of $2.76 on the day, the dollar volume was approximately $0.53 million. The shares have shown a negative half year performance of -45.24% and its price on 01/24/23 gained nearly 17.95%. Currently, there are 8.14M common shares owned by the public and among those 7.07M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 2 analysts who have offered their price forecasts for COCP have a consensus price objective of $22.50. The analysts have set the share’s price value over the next 12 months at a high of $35.00 and a low of $10.00. The average price target is 86.46% above its recent price level and an upside to the estimated low will see the stock gain 72.4% over that period. But an upside of 92.11% will see the stock hit the forecast high price target while median target price for the stock is $22.50.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Cocrystal Pharma Inc. are Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market Index owns 0.19 million shares of the company’s stock, all valued at over $0.37 million. Vanguard Extended Market Index Fu bought 187.0 shares to see its total holdings expand to 70301.0 shares valued at over $0.14 million and representing 0.86% of the shares outstanding. Fidelity Extended Market Index Fu now owns shares totaling to 0.56% of the shares outstanding.
Shares of Cocrystal Pharma Inc. (NASDAQ: COCP) opened at $2.39, up $0.05 from a prior closing price of $2.34. However, the script later moved the day high at 2.8000, up 17.95%. The company’s stock has a 5-day price change of 18.97% and 23.77% over the past three months. COCP shares are trading 41.54% year to date (YTD), with the 12-month market performance down to -56.60% lower. It has a 12-month low price of $1.74 and touched a high of $7.56 over the same period. COCP has an average intraday trading volume of 44.19K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 31.13%, 12.62%, and -31.25% respectively.
Institutional ownership of Cocrystal Pharma Inc. (NASDAQ: COCP) shares accounts for 20.60% of the company’s 8.14M shares outstanding. Mutual fund holders own 4.21%, while other institutional holders and individual stakeholders account for 9.42% and — respectively.
It has a market capitalization of $23.40M and a beta (3y monthly) value of 0.94. The earnings-per-share (ttm) stands at -$4.68. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.25% over the week and 7.84% over the month.
Analysts forecast that Cocrystal Pharma Inc. (COCP) will achieve an EPS of -$0.48 for the current quarter, -$0.56 for the next quarter and -$2.68 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.48 while analysts give the company a high EPS estimate of -$0.48. Comparatively, EPS for the current quarter was -$0.48 a year ago. Earnings per share for the fiscal year are expected to increase by 8.10%, and 37.70% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate Cocrystal Pharma Inc. (COCP) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 0 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the COCP, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on July 08, 2020, with the firm’s price target at $5.